Smoldering Multiple Myeloma
"Smoldering Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.
| Descriptor ID |
D000075122
|
| MeSH Number(s) |
C04.834.794 C15.378.147.542.820 C15.378.147.780.838 C20.683.460.820 C20.683.780.838
|
| Concept/Terms |
Smoldering Multiple Myeloma- Smoldering Multiple Myeloma
- Multiple Myeloma, Smoldering
- Smoldering Multiple Myelomas
- Smoldering Myeloma
- Myeloma, Smoldering
- Smoldering Myelomas
- Asymptomatic Multiple Myeloma
- Asymptomatic Multiple Myelomas
- Multiple Myeloma, Asymptomatic
- Multiple Myelomas, Asymptomatic
|
Below are MeSH descriptors whose meaning is more general than "Smoldering Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Smoldering Multiple Myeloma".
This graph shows the total number of publications written about "Smoldering Multiple Myeloma" by people in this website by year, and whether "Smoldering Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Smoldering Multiple Myeloma" by people in Profiles.
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.